Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 86 results for peripheral arterial disease

  1. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA394

  2. Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia (IPG773)

    Evidence-based recommendations on percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. This involves making a hole between a blocked artery and a vein, allowing the blood to flow into the leg beyond the blockage.

    Interventional procedures guidance
    Published
    18 October 2023
    View recommendations

    Sections for IPG773

  3. Ticagrelor for the treatment of acute coronary syndromes (TA236)

    Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA236

  4. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    6 October 2021
    View recommendations

    Sections for TA733

  5. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued Reference number: GID-MT517

    Medical technologies guidance
    Discontinued

  6. The geko device for reducing the risk of venous thromboembolism (MTG19)

    Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.

    Medical technologies guidance
    Published
    25 June 2014
    View recommendations

    Sections for MTG19

  7. Supervised exercise programmes for treating people with intermittent claudication:- What is the clinical and cost effectiveness of supervised exercise programmes compared with unsupervised exercise for treating people with intermittent claudication, taking into account the effects on long-term outcomes and continuing levels of exercise?

    and unsupervised exercise. The trial should enrol people with peripheral arterial disease-related claudication, but exclude those with...

    Research recommendation
    Published
    9 June 2015

  8. Overweight and obesity management (QS212)

    This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    5 August 2025
    View quality statements

    Sections for QS212

  9. Chronic kidney disease in adults (QS5)

    This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    27 July 2017
    View quality statements

    Sections for QS5

  10. Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (IPG380)

    Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.

    Interventional procedures guidance
    Published
    23 February 2011
    View recommendations

    Sections for IPG380

  11. A trial comparing the long-term effectiveness (beyond 24 weeks) of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate and placebo would be beneficial. It should collect utility data as well as walking distance outcomes.

    for the treatment of intermittent claudication in people with peripheral arterial disease Number TA223 Date issued May 2011 Other

    Research recommendation
    Published
    9 June 2015

  12. The committee recommends collecting further data on clinical outcomes such as time to healing, and incorrect use of compression and its associated adverse consequences when possible.

    Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers Number DG52...

    Research recommendation
    Published
    11 July 2023

  13. The committee recommends collecting further data on the impact of the automated devices on time to treatment for people with leg ulcers to reduce uncertainty in the economic modelling.

    Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers Number DG52...

    Research recommendation
    Published
    11 July 2023

  14. Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IPG653)

    Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults. This involves placing a new bioprosthetic valve inside a failing bioprosthetic valve.

    Interventional procedures guidance
    Published
    26 June 2019
    View recommendations

    Sections for IPG653

  15. The committee recommends more research on diagnostic accuracy in people with leg ulcers. The following considerations should be made when doing this research:

    Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers Number DG52...

    Research recommendation
    Published
    11 July 2023